"Aramchol Resolves NASH Without Worsening Of Fibrosis In Phase 2b Study" - Talitha Bennett
Galmed Pharmaceuticals announced topline results from a phase 2b study of Aramchol, a once-daily liver-targeted stearoyl-Coenzyme A desaturase 1 modulator designed for the treatment of nonalcoholic steatohepatitis, according to a press release. “Data from my laboratory submitted to an upcoming conference confirm by transcriptomic analysis a broad anti-fibrotic effect of Aramchol in fibrogenic hepatic stellate cells, which is complementary to the data seen in this phase 2b, biopsy-based clinical study,” Scott Friedman, MD, dean for therapeutic discovery and chief of the division of liver diseases at the Icahn School of Medicine at Mount Sinai said in the release. “In my view, these results, together with its safety and tolerability, place Aramchol among the leading frontline therapeutic candidates under investigation for NASH.”
- Scott Friedman, MD, Dean, Therapeutic Discovery, Fishberg Professor, Medicine, Professor, Liver Diseases, Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, Chief, Liver Diseases, The Mount Sinai Health System